Invokana Lawsuit Plaintiffs Note Possible Dangerous Adverse Events After Recent FDA Public Safety Warning

March 24, 2016 – – TheProductLawyers.com reports on several lawsuits which have been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson) discussing their type-2 diabetes drug Invokana. This new-generation drug was the first of a group of similar drugs released known as SGLT2 class inhibitors. Recent FDA adverse event reports concerning these types of drugs, however, seem to note that plaintiffs who have recently filed lawsuits against the drugs may be just the first of many.

According to FDA adverse event reports, some patients who have used Invokana have claimed that it caused them to develop a potentially life-threatening condition known as diabetic ketoacidosis. Diabetic ketoacidosis occurs when the body’s bloodstream contains excess toxic acid. It has been reported to develop in as little as 24-hours, and can cause patients to enter comatose states or even pass away if it remains untreated.

One of the initial lawsuits to be filed in the U.S. against Invokana manufacturers alleging the development of diabetic ketoacidosis occurred on December 15th of 2015. The suit was filed under case number 1:15-cv-00636 in Southern Alabama U.S. District Court. Details from documents concerning the filing show that the plaintiff claims to have begun taking Invokana in December of 2014, and to have stopped quickly after this when she discovered that she had developed diabetic ketoacidosis.

An alarmingly similar lawsuit was filed just five days before this, on December 10th of 2015. This suit was filed in the Court of Common Pleas in Philadelphia, Pennsylvania under case number 15-12-00653. Court document details note that the plaintiff in this suit reported taking Invokana starting in November of 2014, but stopping all use of the drug just 3 months later when he also developed diabetic ketoacidosis.

This diabetic ketoacidosis concern was part of the topic of a recent U.S. Food and Drug Administration (FDA) public safety announcement. Additionally, the FDA has required Invokana manufacturer Johnson & Johnson to change the diabetes drug’s warning label to properly warn consumers regarding the potential development of diabetic ketoacidosis and urinary tract infections. The agency has asked patients currently taking the drug to watch closely for any symptoms of diabetic ketoacidosis development, which can include nausea and vomiting, frequent urination, trouble breathing, excess fatigue, and abdominal pain.

The attorneys of Banville Law understand how concerning these potential side effect links will be for many. They are dedicated to generating broad public knowledge of all important product information. To better accomplish this, they currently sponsor online resource website TheProductLawyers.com. In addition, the attorneys of Banville Law are working to help anyone who believes that their use of Invokana or similar drugs led to health problems to fully investigate their legal rights. Affected individuals may be eligible for significant compensation through legal action. To help those seeking justice, the attorneys of Banville Law are also offering complimentary legal consultations to those affected at this time.

To request additional information or ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008881